Bispecific anti-PD-1/LAG-3 antibodies for treatment of advanced or metastatic solid tumors: a patent evaluation of US2018326054
| Autor: | Jorge Cebada, Amira Flores, Cindy Bandala, Martin Perez-Santos, Nemesio Villa-Ruano, Ian Lizaliturri-Flores |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
animal diseases
medicine.medical_treatment Programmed Cell Death 1 Receptor chemical and pharmacologic phenomena 01 natural sciences Patents as Topic Mice 03 medical and health sciences 0302 clinical medicine Immune system Antigens CD Neoplasms Antibodies Bispecific Drug Discovery medicine Animals Humans Pharmacology biology business.industry Anti pd 1 Cancer General Medicine Immunotherapy biochemical phenomena metabolism and nutrition medicine.disease Lymphocyte Activation Gene 3 Protein 0104 chemical sciences Pancreatic Neoplasms 010404 medicinal & biomolecular chemistry 030220 oncology & carcinogenesis Cancer research biology.protein bacteria Antibody business |
| Zdroj: | Expert Opinion on Therapeutic Patents. 30:487-494 |
| ISSN: | 1744-7674 1354-3776 |
| Popis: | Due to the primary role of PD-1 and LAG-3 in regulating the immune response in tumors, there is a need to develop therapies focused on the inhibition of PD-1 and LAG-3 in order to improve the immune response in patients with cancer. The authors of US2018326054 patent propose a method to eradicate cancer by using bispecific anti-PD-1/LAG-3 antibodies.The US2018326054 patent describes anti-PD-1/LAG3 antibodies, pharmaceutical composition that contains it, and their application for cancer treatment, particularly pancreatic carcinoma. Proof concept and preclinical results show anti-PD-1/LAG-3 bispecific antibodies bind and are internalized by CD4 + T cells thereby increasing their effector functions (release of Granzyme B and INF-γ) in the presence of tumor cells, and completely suppress tumors in a murine model.Anti-PD-1/LAG-3 bispecific antibodies of the US2018326054 patent are new in a general concept, but treatment data is only shown for pancreatic carcinoma. The results to be obtained in future clinical trials of safety and efficacy could conclude whether these bispecific anti-PD-1/LAG-3 antibodies will be useful in a cancer treatment scheme. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|